BeyondSpring Q1 net loss $2.4M from continuing ops; cash $7.9M; AACR data supports Plinabulin-ADC combo

BeyondSpring Inc.

Net loss from continuing operations $2.4M vs $2.6M YoY; discontinued ops loss $4.3M.
Cash and short-term investments $7.9M as of March 31, 2026.
AACR 2026 data: Plinabulin enhances efficacy/tolerability of topoisomerase inhibitor–based ADC regimens.
ST-01156 (RBM39 degrader) advanced to Phase 1; first dose cohort completed.
SEED's operations reported as discontinued due to planned sale of preferred shares.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001171843-26-003344

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.